FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Shingles is an acute, unilateral, self-limiting inflammatory disease of cerebral
ganglia and the ganglia of posterior nerve roots and peripheral nerves in a
segmented distribution, caused by Varicella Zoster virus (VZV) - the chicken
pox virus.
Prodromal symptoms that herald HZ include pruritus, dysesthesia, and pain along
the distribution of the involved dermatome
- this pre-eruptive pain may precede the rash by several days and may be mistaken
for myocardial infarction, biliary or renal colic, pleurisy, dental pain,
glaucoma, duodenal ulcer, or appendicitis, leading to misdiagnosis and potentially
mistreatment
- in rare instances, the nerve pain is not accompanied by a skin eruption,
a condition known as zoster sine herpete (1)
Herpes zoster (HZ) or shingles is a painful condition caused by reactivation
of the Varicella Zoster virus (VZV) within the dorsal root or cranial nerve
ganglia (1,2)
- the primary infection which causes varicella (chicken pox) results in
- migration of the virus from skin lesions to spinal and cranial sensory
ganglia where it becomes dormant
- the development of VZV specific humoral and cell-mediated immunity (3)
- reactivation of the virus occurs when the cell mediated immunity wanes (1)
- following reactivation, the virus spreads thorough the affected sensory
nerve, causing neuronal damage and reach the corresponding dermatome in the
skin where a vesicular rash develops (3)
VZV (not HZ) can be transmitted to seronegative contact by an individual with
HZ.
- it is less contagious than varicella - household transmission rate of HZ
(to cause varicella) is 15% (3)
HZ usually occurs only once in life. Around 4-5% of patients may experience
a recurrence (4).
Classic skin findings are grouped vesicles on a red base in a unilateral, dermatomal
distribution.
- however, the lesions of HZ progress through stages, beginning as red
macules and papules that, in the course of 7 to 10 days, evolve into vesicles
and form pustules and crusts. Complete healing may take more than 4 weeks
(5)
- key clinical feature of shingles is a dermatomal eruption of vesicles
often preceded by pain and paraesthesia by several days. Erythema precedes
the development of vesicles. The vesicles may become pustular 2-3 days
following eruption. A tender lymphadenopathy (local) is common in the
early stages of the rash. There is increased itching and burning. The
affected area may remain depigmented and often it is hypoalgesic.
- sites affected:
- most commonly, the lower thoracic region
- ophthalmic division of the trigeminal nerve
- occasionally motor nerves, causing paralysis - for example facial paralysis
in Ramsay Hunt syndrome, or urinary retention
Disseminated HZ occurs primarily in immunocompromised patients; it usually
presents with a dermatomal eruption followed by dissemination but may also present
with a diffuse varicella-like eruption (5)
Complications are seen in 13-40% of patients.
- postherpetic neuralgia (PHN) is the commonest complication
- incidence of PHN is generally estimated to be between 10 and 20% of cases
of HZ (up to 30% in the elderly)
- 80% of all PHN cases are reported in patients over the age of 50 years
(4)
Click
here for example images of this condition
Herpes zoster lesions contain high concentrations of VZV, which can be spread
by contact and by the airborne route and which can cause primary varicella in
exposed, susceptible persons. Less contagious than primary varicella, HZ is
only contagious after the rash appears and until the lesions crust. Risk of
transmission is reduced further if lesions are covered
Reference:
- (1) Werner RN et
al. European consensus-based (S2k) Guideline on the Management of Herpes
Zoster - guided by the European Dermatology Forum (EDF)
in cooperation with the European Academy of Dermatology
and Venereology (EADV), Part 1: Diagnosis. J Eur Acad
Dermatol Venereol. 2017;31(1):9-19.
- (2) Fashner J, Bell
AL. Herpes zoster and postherpetic neuralgia: prevention and management.
Am Fam Physician. 2011;83(12):1432-7.
- (3) Johnson
RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management,
and disease and economic burden in Europe: a multidisciplinary perspective. Ther
Adv Vaccines. 2015;3(4):109-20.
- (4) Armando
S, Nicoletta V, Sara P, Matilde G, Silvia L, et al. Herpes Zoster: New Preventive
Perspectives. J Dermatolog Clin Res. 2015;3(1):1042
- (5) Homler
H.Herpes zoster: query and concern. Mayo Clin Proc. 2009 Jul;84(7):663; author
reply 663-4.
Last edited 12/2018 and last reviewed 04/2021
Links: